Cell therapy: Showing cells the way home
Author(s)
Heinelt, Martina; Karp, Jeffrey Michael; Levy, Oren
DownloadHeinelt-2015-Cell therapy.pdf (511.0Kb)
PUBLISHER_CC
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
The clinical potential of cell-based therapies is limited by poor targeting of systemically infused cells to diseased tissues. In our recent study, we have
developed a multi-step screening platform to identify small molecules that boost the homing properties of mesenchymal stem cells (MSCs) to sites of inflammation. First, a medium-throughput screen was designed to identify small molecules that upregulate surface expression of the homing integrin, cd11a (integrin αL). Ro-31-8425, a kinase inhibitor, was identified as the most potent inducer of cd11a surface expression, and was also shown to significantly increase MSC firm adhesion to the endothelial ligand of cd11a, ICAM-1, using a microfluidics-based firm adhesion assay. Finally, systemically infused Ro-31-8425-pretreated MSCs displayed improved homing to sites of inflammation and a superior anti-inflammatory impact in a murine ear inflammation model.
Date issued
2015-07Department
Harvard University--MIT Division of Health Sciences and TechnologyJournal
Oncotarget
Publisher
Impact Journals/National Center for Biotechnology Information (U.S.)
Citation
Heinelt, Martina, Jeffrey M. Karp, and Oren Levy. "Cell therapy: Showing cells the way home." Oncotarget 6(20) (2015). © 2015 Impact Journals, LLC.
Version: Final published version
ISSN
1949-2553